SERB Acquires US Rights from SFJ for Bentracimab
Shots:
- SERB retains an exclusive US right to the ticagrelor reversal agent bentracimab. SFJ will lead an ongoing clinical trial of bentracimab & will submit the BLA to the US FDA, expected to file in 2023 in collaboration with SERB
- The collaboration will use SERB’ to advance bentracimab. The prespecified interim analysis results from a P-III trial (REVERSE-IT) showed that bentracimab can reverse the antiplatelet effects of ticagrelor, and was well tolerated with minor AEs & the results were published in the NEJM
- Ticagrelor was marketed by AstraZeneca as Brilinta. If bentracimab is approved by the US FDA, it allows patients to benefit from the antithrombotic effect of ticagrelor, preventing vascular events & reducing the risk of death
Ref: Globenewswire | Image: SERB
Related News:- PhaseBio Signs a Supply Agreement with BioVectra to Support the Development and Commercialization of Bentracimab
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
